Facet Biotech will get a milestone payment of $15 million from Bristol-Myers Squibb after it started enrolling patients into a Phase II trial of elotuzumab, a multiple myeloma drug. Meanwhile, Bristol-Myers decided not to expand its development deal with Facet for PDL241, an experimental treatment for immune system disorders.

Related Summaries